Quipt Home Medical on Preliminary List to Join Russell Microcap® Index
06 June 2022 - 9:30PM
Quipt Home Medical Corp. (“
Quipt” or the
“
Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based
leader in the home medical equipment industry, focused on
end-to-end respiratory care, is very pleased to announce it is on a
preliminary list dated June 3, 2022 issued by the Russell Microcap
Index to join the Russell Microcap Index at the conclusion of the
2022 Russell indexes annual reconstitution, effective after the
U.S. market opens on June 27, 2022.
Membership in the Russell Microcap® Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
“Our inclusion to the Russell Microcap Index
would be an important milestone for our Company and its
shareholders, as we continue on our exciting growth path of
becoming a leader in at home respiratory care for patients across
the United States. We believe joining this index would
significantly bolster our visibility and access to the global
investment community and we are excited at the prospect of being
included alongside some of the most innovative companies in the
United States. This inclusion would truly reflect the substantial
growth experienced by our Company and our evolution as a publicly
traded company over the last several years,” commented Greg
Crawford, CEO and Chairman of Quipt. “We are extremely well
positioned to continue executing on our three-pronged growth
strategy which has yielded robust and consistent financial
performance and look forward to providing our shareholders updates
over the near term.”
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $12
trillion in assets are benchmarked against Russell’s US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell Microcap®
Index and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About Quipt Home
Medical Corp.
The Company provides in-home monitoring and
disease management services including end-to-end respiratory
solutions for patients in the United States healthcare market. It
seeks to continue to expand its offerings to include the management
of several chronic disease states focusing on patients with heart
or pulmonary disease, sleep disorders, reduced mobility, and other
chronic health conditions. The primary business objective of the
Company is to create shareholder value by offering a broader range
of services to patients in need of in-home monitoring and chronic
disease management. The Company’s organic growth strategy is to
increase annual revenue per patient by offering multiple services
to the same patient, consolidating the patient’s services, and
making life easier for the patient. For further information visit,
www.Quipthomemedical.com.
About FTSE Russell
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of indexes
that measure and benchmark markets and asset classes in more than
70 countries, covering 98% of the investable market globally. FTSE
Russell index expertise and products are used extensively by
institutional and retail investors globally. Approximately $20
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create ETFs, structured products
and index-based derivatives. For more information, visit
www.ftserussell.com.
Reader Advisories
While the Company is on the June 3, 2022
preliminary list for inclusion on the Russell Microcap Index, no
assurance can be given that it will ultimately on the final
list.
Unless otherwise specified, all dollar amounts
in this press release are expressed in U.S. dollars.Neither the
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Forward-Looking Statements
Certain statements contained in this press
release constitute "forward-looking information" as such term is
defined in applicable Canadian securities legislation. The words
"may", "would", "could", "should", "potential", "will", "seek",
"intend", "plan", "anticipate", "believe", "estimate", "expect"
and similar expressions as they relate to the Company, including:
inclusion on the Russell Microcap® Index and the results of such
inclusion; and the Company believing joining the index would
significantly bolster its visibility and access to the global
investment community; are intended to identify forward-looking
information. All statements other than statements of historical
fact may be forward-looking information. Such statements reflect
the Company's current views and intentions with respect to future
events, and current information available to the Company, and are
subject to certain risks, uncertainties and assumptions,
including, without limitation: the Company meeting the inclusion
standards of the Russell Microcap® Index; and capital market
participants responding to a Nasdaq listing as anticipated. Many
factors could cause the actual results, performance or achievements
that may be expressed or implied by such forward-looking
information to vary from those described herein should one or more
of these risks or uncertainties materialize. Examples of such risk
factors include, without limitation: credit; market (including
equity, commodity, foreign exchange and interest rate); liquidity;
operational (including technology and infrastructure);
reputational; insurance; strategic; regulatory; legal;
environmental; capital adequacy; the general business and economic
conditions in the regions in which the Company operates; the
ability of the Company to execute on key priorities, including the
successful completion of acquisitions, business retention, and
strategic plans and to attract, develop and retain key executives;
difficulty integrating newly acquired businesses; the ability to
implement business strategies and pursue business opportunities;
low profit market segments; disruptions in or attacks (including
cyber-attacks) on the Company's information technology, internet,
network access or other voice or data communications systems or
services; the evolution of various types of fraud or other criminal
behavior to which the Company is exposed; the failure of third
parties to comply with their obligations to the Company or its
affiliates; the impact of new and changes to, or application of,
current laws and regulations; decline of reimbursement rates;
dependence on few payors; possible new drug discoveries; a novel
business model; dependence on key suppliers; granting of permits
and licenses in a highly regulated business; the overall difficult
litigation environment, including in the U.S.; increased
competition; changes in foreign currency rates; increased funding
costs and market volatility due to market illiquidity and
competition for funding; the availability of funds and resources to
pursue operations; critical accounting estimates and changes to
accounting standards, policies, and methods used by the Company;
and the occurrence of natural and unnatural catastrophic events and
claims resulting from such events; as well as those risk factors
discussed or referred to in the Company’s disclosure documents
filed with the securities regulatory authorities in certain
provinces of Canada and available at www.sedar.com. Should any
factor affect the Company in an unexpected manner, or should
assumptions underlying the forward-looking information prove
incorrect, the actual results or events may differ materially from
the results or events predicted. Any such forward-looking
information is expressly qualified in its entirety by this
cautionary statement. Moreover, the Company does not assume
responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and the Company undertakes no obligation to publicly update
or revise any forward-looking information, other than as required
by applicable law.
For further information contact:
Cole StevensVP of Corporate Development
859-300-6455cole.stevens@myquipt.com
Gregory CrawfordChief Executive OfficerQuipt
Home Medical Corp.859-300-6455investorinfo@myquipt.com
Quipt Home Medical (TSXV:QIPT)
Historical Stock Chart
From Apr 2024 to May 2024
Quipt Home Medical (TSXV:QIPT)
Historical Stock Chart
From May 2023 to May 2024